Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights
  • Choose License Type

U.S Intravenous Solution Market, by Solution Type (Saline (Normal saline 0.9% NaCl and Hypertonic saline), Dextran (D5W 5% dextrose in water and Analog Hypertonic Saline), Lactated Ringer’s, Amino Acid, Vitamins & Minerals, Heparin and trace elements, and Mixed Solutions), By Packaging (Ampules, Vials, Cartridges, Bottles, Bags (Large Volume Bags-greater than 250ml and Small Volume Bags-less than 250ml), By Indication (Oncology, Post-Operative Care, General Medicine, Burn Management, Pulmonary Disorders, Cardiovascular Diseases, and Others), and By End User (Hospitals, Clinics, Ambulatory Surgical Centers, Home care Settings, and Others) is estimated to be valued at US$ 2,811.3 million in 2021 and is expected to exhibit a CAGR of 6.1% during the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.

U.S Intravenous Solutions Market- Impact of Coronavirus (COVID-19) Pandemic

Lockdown in various countries due to the pandemic has placed an economic burden on the private healthcare sector. Healthcare providers are facing challenges with regards to declining outpatient’s visits, manpower, equipment, consumables, and other resources to ensure safety in treatment of patients with other diseases. The global COVID-19 pandemic has sharply focused the attention of the world onto critical care of COVID-19 patients. During the early stages of the COVID-19 pandemic, it was a common advice of physicians to aim for a negative fluid balance. Nowadays, a higher occurrence of acute kidney injury requiring renal replacement therapy has been observed, prompting for a more liberal fluid strategy. For instance, the World Health Organization guidelines recommend that patients with COVID-19 in respiratory failure should be treated cautiously with intravenous fluids, especially in settings with limited availability of mechanical ventilation.

  • Use a conservative fluid management strategy for acute respiratory distress syndrome (ARDS) patients without tissue hypoperfusion
  • In resuscitation for septic shock in adults, give 250–500 mL crystalloid fluid as a rapid bolus in the first 15–30 minutes and reassess for signs of fluid overload after each bolus
  • Consider dynamic indices of volume responsiveness to guide volume administration beyond initial resuscitation based on local resources and experience. These indices include passive leg raises, fluid challenges with serial stroke volume measurements, or variations in systolic pressure, pulse pressure, inferior vena cava size, or stroke volume in response to changes in intrathoracic pressure during mechanical ventilation.

Thus, due to lockdown and disruption in supply chain and the increasing demand of healthcare products for patients, this pandemic has hampered the U.S intravenous solution market.

However, the increasing number of product approvals from regulatory bodies, collaborations and partnership strategies adopted by key players are some of the major factors which are expected to drive growth of the U.S intravenous solution market during the forecast period. For instance, in November 2016, Mallinckrodt Pharmaceuticals received U.S. Food and Drug Administration’s (FDA) Prior Approval Supplement for its OFIRMEV (acetaminophen) injection (new drug application) available in an intravenous (IV) bag presentation.

Administration of IV fluids in the patients of cardiac arrhythmia helps in improvement of haemodynamic status in critically ill patients. Thus, the increasing number prevalence of cardiac arrhythmia is expected to provide huge opportunities to the U.S intravenous solution market growth in the near future. For instance, the Centers for Disease Control and Prevention 2014, estimated that 2.7–6.1 million people in the U.S. suffered from atrial fibrillation. With increasing aging population, this number is also expected to increase.

The increasing number of patient admissions in ambulatory surgical centers for surgical procedures, which requires intravenous solutions or infusion for administration of drugs is expected to drive the ambulatory surgical centers (ASCs) segment growth. For instance, according to the H-Cup Journal Report 2017, in the U.S., there were around 17.2 million ambulatory hospital visits recorded in the hospitals.

A person suffering from diarrhea also suffers from intense fluid loss and dehydration. Thus, diarrhea patients are highly prescribed with IV fluids such as saline and vitamins. Increasing prevalence of diarrhea is expected to drive growth of U.S intravenous solution market during the forecast period. For instance, according to the article published in New England Journal of Medicine, April 2014, 179 million cases of acute diarrhea are registered annually in the U.S.

Browse 13 Market Data Tables and 40 Figures spread through 169 Pages and in-depth TOC on U.S Intravenous Solution Market, by Solution Type (Saline (Normal saline 0.9% NaCl and Hypertonic saline), Dextran (D5W 5% dextrose in water and Analog Hypertonic Saline), Lactated Ringer’s, Amino Acid, Vitamins & Minerals, Heparin and trace elements, and Mixed Solutions), By Packaging (Ampules, Vials, Cartridges, Bottles, Bags (Large Volume Bags-greater than 250ml and Small Volume Bags-less than 250ml), By Indication (Oncology, Post-Operative Care, General Medicine, Burn Management, Pulmonary Disorders, Cardiovascular Diseases, and Others), and By End User (Hospitals, Clinics, Ambulatory Surgical Centers, Home care Settings, and Others) - Forecast to 2028"

To know the latest trends and insights related to U.S Intravenous Solution Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/us-intravenous-solution-market-3400

The increasing number of surgeries are expected to propel demand for large volume of Intravenous (IV) solutions. For instance, according to Healthcare Cost and Utilization Project report 2020, a total of 17.2 million hospital visits (as visits or inpatient stays) in the United States included at least one surgery in 2017.

Key Takeaways of the U.S Intravenous Solution Market:

  • The U.S intravenous solution market is expected to exhibit a CAGR of 6.1% during the forecast period (2021-2028) owing to the increasing launches of new intravenous solution injections for the treatment of various issues such as neuromuscular blockade and paralysis, this is expected to boost the market growth over the forecast period. For instance, in 2017, Fresenius Kabi USA, LLC, a provider of medicines and technologies for infusion, transfusion, and clinical nutrition, launched Vecuronium Bromide IV injection in the U.S. The drug is indicated for maintenance of neuromuscular blockade and paralysis.
  • Among solution type, Saline segment is expected to hold major revenue share in 2028, owing to the increasing incidence of gastroenteritis, which is expected to contribute to the growth of the saline segment. For instance, according to the data of National Center of Biotechnology Information 2020, acute viral gastroenteritis accounts for 19 to 21 million cases of diarrheal illnesses annually in the U.S.
  • Major players operating in the U.S intravenous solution market are B. Braun Melsungen AG., Baxter International Inc., Fresenius Kabi USA, LLC, Grifols, S.A., JW Life Science, Amanta Healthcare, Salius Pharma Private Limited, Axa Parenterals Ltd., Vifor Pharma Management Ltd., ICU Medical, Inc., and Pfizer Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.